𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma

✍ Scribed by Yoshida, Takanobu; Okazaki, Nobuo; Yoshino, Masahiro; Okhura, Hisanao; Shimada, Yasuhiro

Book ID
122020155
Publisher
Elsevier Science
Year
1990
Weight
227 KB
Volume
26
Category
Article
ISSN
0277-5379

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Recombinant gamma interferon in advanced
Recombinant gamma interferon in advanced breast cancer: A phase II trial
✍ Hyman B. Muss; Mary Caponera; Patricia J. Zekan; Don V. Jackson; John J. Stuart; πŸ“‚ Article πŸ“… 1986 πŸ› Springer US 🌐 English βš– 365 KB

Fifteen patients with advanced carcinoma of the breast who had failed prior chemotherapy, were treated with recombinant gamma interferon at a dose of 2mg/m2 (1mg = 2.4 X 10(7) international units) intravenously for five consecutive days every other week. The median patient age was 51 and all patient

Phase II trial of recombinant interferon
Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx
✍ Raoudha Mahjoubi; Mounir Bachouchi; Jean-Nicolas Munck; Pierre Busson; Jamel Gas πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 422 KB

## Abstract The presence of Epstein–Barr virus (EBV) genomes in the DNA of tumor cells of undifferentiated carcinoma of nasopharyngeal type (UCNT), associated with significant lymphocytic infiltration of tumor led to therapeutic trials with interferon (IFN) because of its antiviral, antiproliferati